 Naltrexone
"Naltrexone" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
Derivative of noroxymorphone that is the N-cyclopropylmethyl congener of NALOXONE. It is a narcotic antagonist that is effective orally, longer lasting and more potent than naloxone, and has been proposed for the treatment of heroin addiction. The FDA has approved naltrexone for the treatment of alcohol dependence.
| Descriptor ID |
D009271
|
| MeSH Number(s) |
D03.132.577.249.706.550 D03.549.686.750.550 D03.605.497.750.550 D04.615.723.795.706.550
|
| Concept/Terms |
Celupan- Celupan
- Lacer Brand of Naltrexone Hydrochloride
ReVia- ReVia
- Schering-Plough Brand of Naltrexone Hydrochloride
- Schering Plough Brand of Naltrexone Hydrochloride
- Lamepro Brand of Naltrexone Hydrochloride
- United Drug Brand of Naltrexone Hydrochloride
- Orphan Brand of Naltrexone Hydrochloride
- Nemexin
- Bristol-Myers Squibb Brand of Naltrexone Hydrochloride
- Bristol Myers Squibb Brand of Naltrexone Hydrochloride
- Du Pont Brand of Naltrexone Hydrochloride
- Nalorex
Antaxone- Antaxone
- Pharmazam Brand of Naltrexone Hydrochloride
|
Below are MeSH descriptors whose meaning is more general than "Naltrexone".
Below are MeSH descriptors whose meaning is more specific than "Naltrexone".
This graph shows the total number of publications written about "Naltrexone" by people in this website by year, and whether "Naltrexone" was a major or minor topic of these publications.
To see the data from this visualization as text, click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 1984 | 0 | 1 | 1 | | 1989 | 0 | 1 | 1 | | 1993 | 0 | 1 | 1 | | 1994 | 1 | 1 | 2 | | 1995 | 1 | 1 | 2 | | 1996 | 1 | 1 | 2 | | 1997 | 4 | 0 | 4 | | 1998 | 2 | 0 | 2 | | 1999 | 4 | 0 | 4 | | 2000 | 5 | 1 | 6 | | 2001 | 4 | 1 | 5 | | 2002 | 7 | 1 | 8 | | 2004 | 5 | 1 | 6 | | 2005 | 2 | 0 | 2 | | 2006 | 6 | 1 | 7 | | 2007 | 3 | 2 | 5 | | 2008 | 4 | 0 | 4 | | 2009 | 6 | 1 | 7 | | 2010 | 4 | 0 | 4 | | 2011 | 0 | 1 | 1 | | 2012 | 3 | 0 | 3 | | 2013 | 3 | 0 | 3 | | 2014 | 4 | 1 | 5 | | 2015 | 1 | 1 | 2 | | 2016 | 3 | 0 | 3 | | 2017 | 2 | 0 | 2 | | 2019 | 2 | 0 | 2 |
To return to the timeline, click here.
Below are the most recent publications written about "Naltrexone" by people in Profiles.
-
Roche DJO, Trela CJ, Argos M, Jasmine F, Kibriya MG, Ahsan H, King AC. Lack of Association between Opioid-Receptor Genotypes and Smoking Cessation Outcomes in a Randomized, Controlled Naltrexone Trial. Alcohol Alcohol. 2019 Jan 09; 54(5):559-565.
-
Moss J. Identifying and Treating Opioid Side Effects: The Development of Methylnaltrexone. Anesthesiology. 2019 01; 130(1):142-148.
-
Abraham AJ, Andrews CM, Grogan CM, Pollack HA, D'Aunno T, Humphreys K, Friedmann PD. State-Targeted Funding and Technical Assistance to Increase Access to Medication Treatment for Opioid Use Disorder. Psychiatr Serv. 2018 04 01; 69(4):448-455.
-
Grant JE, Potenza MN, Kraus SW, Petrakis IL. Naltrexone and Disulfiram Treatment Response in Veterans With Alcohol Dependence and Co-Occurring Problem-Gambling Features. J Clin Psychiatry. 2017 Nov/Dec; 78(9):e1299-e1306.
-
Janku F, Johnson LK, Karp DD, Atkins JT, Singleton PA, Moss J. Treatment with methylnaltrexone is associated with increased survival in patients with advanced cancer. Ann Oncol. 2016 11; 27(11):2032-2038.
-
Nissen SE, Wolski KE, Prcela L, Wadden T, Buse JB, Bakris G, Perez A, Smith SR. Effect of Naltrexone-Bupropion on Major Adverse Cardiovascular Events in Overweight and Obese Patients With Cardiovascular Risk Factors: A Randomized Clinical Trial. JAMA. 2016 Mar 08; 315(10):990-1004.
-
Wardle MC, Bershad AK, de Wit H. Naltrexone alters the processing of social and emotional stimuli in healthy adults. Soc Neurosci. 2016 12; 11(6):579-91.
-
Roginsky G, Alexoff A, Ehrenpreis ED. Initial Findings of an Open-Label Trial of Low-Dose Naltrexone for Symptomatic Mesenteric Panniculitis. J Clin Gastroenterol. 2015 Oct; 49(9):794-5.
-
Singleton PA, Moss J, Karp DD, Atkins JT, Janku F. The mu opioid receptor: A new target for cancer therapy? Cancer. 2015 Aug 15; 121(16):2681-8.
-
Bress A, Kittles R, Wing C, Hooker SE, King A. Genetic ancestry as an effect modifier of naltrexone in smoking cessation among African Americans: an analysis of a randomized controlled trial. Pharmacogenet Genomics. 2015 Jun; 25(6):305-12.
|
People  People who have written about this concept. _
Similar Concepts
People who have written about this concept.
_
Top Journals
Top journals in which articles about this concept have been published.
|